ID29818A - Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial - Google Patents

Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial

Info

Publication number
ID29818A
ID29818A IDW00200101602A ID20011602A ID29818A ID 29818 A ID29818 A ID 29818A ID W00200101602 A IDW00200101602 A ID W00200101602A ID 20011602 A ID20011602 A ID 20011602A ID 29818 A ID29818 A ID 29818A
Authority
ID
Indonesia
Prior art keywords
angiotensin
treat
receptor antagonists
miocardial infarction
acute
Prior art date
Application number
IDW00200101602A
Other languages
English (en)
Indonesian (id)
Inventor
Jessica M Mann
Pascale Oddou
Eric Michel Neuhart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ID29818A publication Critical patent/ID29818A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW00200101602A 1999-01-26 2000-01-24 Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial ID29818A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99810061 1999-01-26
US46866499A 1999-12-21 1999-12-21

Publications (1)

Publication Number Publication Date
ID29818A true ID29818A (id) 2001-10-11

Family

ID=26153740

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101602A ID29818A (id) 1999-01-26 2000-01-24 Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial

Country Status (25)

Country Link
EP (2) EP1714651A1 (hu)
JP (1) JP2002535367A (hu)
KR (1) KR100674053B1 (hu)
CN (1) CN1337879A (hu)
AT (1) ATE330599T1 (hu)
AU (1) AU766453C (hu)
BR (1) BR0007686A (hu)
CA (1) CA2360691A1 (hu)
CY (1) CY1105257T1 (hu)
CZ (1) CZ20012682A3 (hu)
DE (1) DE60028928T2 (hu)
DK (1) DK1146872T3 (hu)
ES (1) ES2265910T3 (hu)
HK (1) HK1041808B (hu)
HU (1) HUP0105199A3 (hu)
ID (1) ID29818A (hu)
IL (2) IL144216A0 (hu)
NO (1) NO20013459L (hu)
NZ (1) NZ513039A (hu)
PL (1) PL197161B1 (hu)
PT (1) PT1146872E (hu)
RU (2) RU2298405C2 (hu)
SI (1) SI1146872T1 (hu)
SK (1) SK10522001A3 (hu)
WO (1) WO2000044378A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9132001A3 (en) * 1998-12-23 2002-01-07 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7076287B2 (en) * 2000-12-29 2006-07-11 Ge Medical Systems Information Technologies, Inc. System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction
EP1448190A2 (en) * 2001-10-18 2004-08-25 Novartis AG Salts formed of an at1-receptor antagonist and a cardiovascular agent
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
MXPA04011428A (es) * 2002-05-17 2005-02-14 Novartis Ag Combinacion de bloqueador del receptor de angiotensina ii y bloqueador-beta para la prevencion secundaria de infarto de miocardio.
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN104086623B (zh) * 2014-07-02 2017-05-24 牡丹江友搏药业有限责任公司 一种新的具有降压和细胞保护作用的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Also Published As

Publication number Publication date
DE60028928T2 (de) 2007-01-04
IL144216A (en) 2007-07-04
EP1146872B1 (en) 2006-06-21
CY1105257T1 (el) 2010-03-03
AU766453C (en) 2004-11-25
JP2002535367A (ja) 2002-10-22
EP1714651A1 (en) 2006-10-25
RU2345790C2 (ru) 2009-02-10
SI1146872T1 (sl) 2006-12-31
NO20013459L (no) 2001-09-05
HK1041808A1 (en) 2002-07-26
KR20020002379A (ko) 2002-01-09
KR100674053B1 (ko) 2007-01-25
ATE330599T1 (de) 2006-07-15
ES2265910T3 (es) 2007-03-01
NZ513039A (en) 2003-11-28
CN1337879A (zh) 2002-02-27
CZ20012682A3 (cs) 2001-10-17
HK1041808B (zh) 2007-01-19
PL197161B1 (pl) 2008-03-31
SK10522001A3 (sk) 2001-12-03
EP1146872A1 (en) 2001-10-24
AU766453B2 (en) 2003-10-16
RU2298405C2 (ru) 2007-05-10
WO2000044378A1 (en) 2000-08-03
CA2360691A1 (en) 2000-08-03
DK1146872T3 (da) 2006-10-16
RU2006135205A (ru) 2008-04-10
PT1146872E (pt) 2006-10-31
HUP0105199A2 (hu) 2002-04-29
BR0007686A (pt) 2001-11-06
HUP0105199A3 (en) 2004-11-29
IL144216A0 (en) 2002-05-23
NO20013459D0 (no) 2001-07-12
AU2439700A (en) 2000-08-18
DE60028928D1 (de) 2006-08-03

Similar Documents

Publication Publication Date Title
CY1105257T1 (el) Χρηση των ανταγωνιστων των υποδοχεων της αγγειοτενσινης ii στην θepαπεια του οξεος εμφραγματος του μυοκαρδιου
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
DK1588706T3 (da) Valsartantablet
NO963064D0 (no) Behandling av normotensive glaukoma med angiotensin-II-antagonister
AU2002226365A1 (en) Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
MXPA03009595A (es) Uso de antagonistas del canal de sodio neuronal para control de ectoparasitos de animales homeotermicos.
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
RS78004A (en) Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
MY135441A (en) Therapeutic treatment
BR0000486A (pt) Antagonistas do neuropeptìdeo y
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine